S&P 500
(0.12%) 5 303.27 points

Dow Jones
(0.34%) 40 004 points

Nasdaq
(-0.07%) 16 686 points

Oil
(-0.12%) $79.96

Gas
(1.37%) $2.66

Gold
(0.88%) $2 438.70

Silver
(4.02%) $32.52

Platinum
(0.89%) $1 099.70

USD/EUR
(-0.03%) $0.920

USD/NOK
(-0.06%) $10.67

USD/GBP
(0.02%) $0.787

USD/RUB
(0.09%) $91.05

Realtime updates for Astellas Pharma Inc. [4503.T]

Exchange: JPX Sector: Healthcare Industry: Drug Manufacturers—General

Last Updated19 May 2024 @ 22:35

25% discount on Stockinvest.us - Use code: Podcast

2.66% ¥ 1 526.50

Live Chart Being Loaded With Signals

Commentary (19 May 2024 @ 22:35):

Astellas Pharma Inc. engages in the manufacture, marketing, import, and export of pharmaceuticals worldwide. It provides XTANDI, an androgen receptor signaling inhibitor for prostate cancer; XOSPATA, a FLT3 inhibitor for adult patients with relapsed or refractory acute myeloid leukemia with a FLT3 mutation-positive; PADCEV, a treatment solution for adult patients with locally advanced or metastatic urothelial cancer; Betanis/Myrbetriq/BETMIGA, a beta-3 adrenergic receptor agonist for the treatment of urgency, urinary frequency, and urge urinary incontinence; Evrenzo, an oral treatment for anemia associated with chronic kidney disease; and Prograf and Advagraf/Graceptor/ASTAGRAF, which are immunosuppressants used to suppress organ rejection following a transplant...

Stats
Today's Volume	2.56M
Average Volume	8.68M
Market Cap	2 737.16B
EPS	¥0 ( 2024-04-25 )
Next earnings date	( ¥9.88 ) 2024-07-29
Last Dividend	¥30.00 ( 2023-03-30 )
Next Dividend	¥0 ( N/A )
P/E	569.59
ATR14	¥0.864 (0.06%)

Volume Correlation

Long: -0.30 (neutral)

Short: -0.32 (neutral)

Signal:(49.675) Neutral

Astellas Pharma Inc. Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Astellas Pharma Inc. Correlation - Currency/Commodity

0.16
( neutral )

0.46
( neutral )

0.58
( weak )

0.61
( weak )

-0.54
( weak negative )

-0.71
( moderate negative )

Astellas Pharma Inc. Financials

Annual	2023
Revenue:	¥1 603.67B
Gross Profit:	¥1 212.37B (75.60 %)
EPS:	¥9.50

FY	2023
Revenue:	¥1 603.67B
Gross Profit:	¥1 212.37B (75.60 %)
EPS:	¥9.50

FY	2022
Revenue:	¥1 518.62B
Gross Profit:	¥1 230.27B (81.01 %)
EPS:	¥54.24

FY	2022
Revenue:	¥1 296.16B
Gross Profit:	¥1 043.15B (80.48 %)
EPS:	¥67.08

Financial Reports:

No articles found.

Astellas Pharma Inc. Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
¥30.00 (N/A)	¥0 (N/A)	¥30.00 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)

Astellas Pharma Inc. Dividend Information - Ex Dividend Knight

Dividend Sustainability Score: 8.06 - good (80.57%) | Divividend Growth Potential Score: 4.81 - Stable (3.74%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	¥3.00	2000-03-28
Last Dividend	¥30.00	2023-03-30
Next Dividend	¥0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	48	--
Total Paid Out	¥591.00	--
Avg. Dividend % Per Year	0.00%	--
Score	3.41	--
Div. Sustainability Score	8.06
Div.Growth Potential Score	4.81
Div. Directional Score	6.43	--

Next Divdend (Est)
(2024-07-03)

¥0 Estimate 1.26 %

Dividend Stability

0.10 Bad

Dividend Score

3.41

Pay Frequency

Semi-Annually

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.

Top 10 dividend Companies for JPX

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
8542.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0	0.00%
7867.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0	0.00%
7011.T	Ex Dividend Knight	2023-09-28	Annually	0	0.00%
6358.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0	0.00%
5218.T	Ex Dividend Junior	2023-10-30	Annually	0	0.00%
4320.T	Ex Dividend Junior	2023-09-28	Annually	0	0.00%
3486.T	Ex Dividend Junior	2023-12-28	Annually	0	0.00%
2715.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0	0.00%
9613.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0	0.00%
8154.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.00805	1.500	9.84	10.00	[0 - 0.5]
returnOnAssetsTTM	0.00362	1.200	9.88	10.00	[0 - 0.3]
returnOnEquityTTM	0.00817	1.500	-1.020	-1.530	[0.1 - 1]
payoutRatioTTM	9.04	-1.000	10.00	-10.00	[0 - 1]
currentRatioTTM	0.929	0.800	-0.354	-0.283	[1 - 3]
quickRatioTTM	0.687	0.800	-0.663	-0.530	[0.8 - 2.5]
cashRatioTTM	0.261	1.500	9.66	10.00	[0.2 - 2]
debtRatioTTM	0.258	-1.500	5.70	-8.56	[0 - 0.6]
interestCoverageTTM	8.97	1.000	7.79	7.79	[3 - 30]
operatingCashFlowPerShareTTM	96.75	2.00	10.00	10.00	[0 - 30]
freeCashFlowPerShareTTM	51.15	2.00	10.00	10.00	[0 - 20]
debtEquityRatioTTM	0.576	-1.500	7.69	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.797	1.000	0.0457	0.0457	[0.2 - 0.8]
operatingProfitMarginTTM	0.0672	1.000	-0.657	-0.657	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0.190	1.000	-0.0541	-0.0541	[0.2 - 2]
assetTurnoverTTM	0.449	0.800	-0.338	-0.271	[0.5 - 2]
Total Score				8.06

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	208.49	1.000	10.00	0	[1 - 100]
returnOnEquityTTM	0.00817	2.50	-0.656	-1.530	[0.1 - 1.5]
freeCashFlowPerShareTTM	51.15	2.00	10.00	10.00	[0 - 30]
dividendYielPercentageTTM	4.71	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	96.75	2.00	10.00	10.00	[0 - 30]
payoutRatioTTM	9.04	1.500	10.00	-10.00	[0 - 1]
pegRatioTTM	-10.89	1.500	-10.00	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.109	1.000	9.77	0	[0.1 - 0.5]
Total Score				4.81

Astellas Pharma Inc. Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Astellas Pharma Inc.

Astellas Pharma Inc. engages in the manufacture, marketing, import, and export of pharmaceuticals worldwide. It provides XTANDI, an androgen receptor signaling inhibitor for prostate cancer; XOSPATA, a FLT3 inhibitor for adult patients with relapsed or refractory acute myeloid leukemia with a FLT3 mutation-positive; PADCEV, a treatment solution for adult patients with locally advanced or metastatic urothelial cancer; Betanis/Myrbetriq/BETMIGA, a beta-3 adrenergic receptor agonist for the treatment of urgency, urinary frequency, and urge urinary incontinence; Evrenzo, an oral treatment for anemia associated with chronic kidney disease; and Prograf and Advagraf/Graceptor/ASTAGRAF, which are immunosuppressants used to suppress organ rejection following a transplant. The company also offers mirabegron for the treatment of neurogenic detrusor overactivity in pediatric patients; Vesicare for OAB treatment; Eligard to treat prostate cancer; Harnal/Omnic for benign prostatic hyperplasia treatment; and Funguard/MYCAMINE, an antifungal agent. The company has a clinical trial collaboration with Merck & Co., Inc.; CytomX Therapeutics, Inc.; and an agreement with BANDAI NAMCO Entertainment Inc. for the development of smartphone exercise support application. It also has strategic research alliance with Harvard University for the research and development of therapeutics and technologies of mutual interest; research collaboration with Actinium Pharmaceuticals, Inc. to develop targeted radiotherapies using its Antibody Warhead Enabling technology platform, as well as agreement with Zenith Epigenetics Ltd. to evaluate ZEN-3694; and collaboration agreement with Cytokinetics, Incorporated. The company has a strategic collaboration and license agreement with Minovia Therapeutics Ltd. for the research, development, and commercialization of cell therapy programs for diseases caused by mitochondrial dysfunction. Astellas Pharma Inc. was founded in 1923 and is headquartered in Tokyo, Japan.

About Live Signals

The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.

The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators

Investing in the stock market involves risk and the value of your investment can fluctuate. The stock market can be affected by a variety of factors, including economic conditions, company performance, and global events. There is no guarantee of profit and you could lose money. Please consider your financial situation, investment goals, and level of risk tolerance before making any investment decisions. Consult with a financial advisor for personalized advice.